Indigo Light Prevented Myopia in a Near-Primate Model
A wavelength missing from most standard indoor lighting stopped myopia from developing in tree shrews. The finding puts a specific color of light — indigo light — at the center of a new explanation for why childhood nearsightedness has become so common in modern indoor environments.
The experiment matters because the tree shrew visual system resembles the human eye in important ways. When the animals were exposed to indigo light in the 419 to 446 nanometer range, the usual elongation of the eye that drives myopia did not occur. In this model, the intervention did not merely slow progression. It completely prevented the disorder from developing.
That kind of outcome is hard to ignore in vision science.
Why Eye Elongation Matters in Childhood Myopia
Myopia develops when the eye grows too long from front to back. Light then falls in front of the retina instead of directly on it, and distant objects blur. Glasses and contact lenses correct the focus problem, but they do not change the underlying growth pattern. Severe myopia also raises the long-term risk of retinal detachment, glaucoma, and macular degeneration, which makes prevention more than a quality-of-life issue.
The surge in childhood myopia has been linked for years to more time indoors and more time on screens, but this work shifts attention from behavior alone to the light spectrum itself. Indoor spaces are not just dimmer than sunlight; they are different. Standard white LEDs peak around 450 nanometers and provide useful vision light, yet they contain relatively little indigo light, the short-wavelength band that appears to influence nonvisual eye biology.
In other words, the eye may be receiving brightness without receiving the right spectral signal.
A Lens That Filters Out the Wrong Wavelengths
The study built on earlier mouse work showing that violet light near 380 nanometers could reduce myopia and that opsin 5, or OPN5, was necessary for that protective effect. Tree shrews did not respond the same way. Their lenses, like human lenses, block most wavelengths below about 400 nanometers, which means the ultra-violet band used in mice does not reach the retina efficiently in this model or in people.
That difference forced a practical pivot. Investigators searched for a slightly longer wavelength that could still stimulate OPN5 while passing through the lens. Indigo light became the answer. According to the experiment, it was the most effective wavelength for preventing myopia in tree shrews.
The biological logic is straightforward: if the lens filters out one part of the spectrum, the therapy has to land in a range the eye can actually receive. The right wavelength can still engage the signaling pathway without relying on ultra-violet light that never makes it to the back of the eye.
Tree Shrews as a Human-Relevant Test System
Tree shrews were not chosen for novelty. Their eyes share anatomical and optical features with human eyes, making them useful for refractive-development studies. Investigators used tiny spectacles designed for tree shrews to create a strong myopia signal in one eye, while the other eye served as a comparison. That setup allowed direct tracking of how different wavelengths altered eye growth.
Eye shape and axial length were measured with a biometer, and an autorefractor tracked refraction over time. Those tools captured the core endpoints that matter in myopia research: whether the eye becomes longer and whether the refractive state shifts toward nearsightedness.
The result was stark. Indigo light blocked the structural change before it could take hold.
What Indoor Lighting May Be Missing
The findings support a broader hypothesis: modern indoor lighting may expose developing eyes to a narrowed slice of the spectrum compared with natural sunlight. Humans evolved outdoors, not under white LEDs, and the eye may depend on a richer mix of wavelengths for normal refractive development. Full-spectrum sunlight provides that mix. Standard indoor lighting usually does not.
The concern is not limited to children with screens. It reaches into the environment itself, where classrooms, homes, and daycare centers may be delivering abundant illumination but incomplete biological information. The work suggests that the problem may involve more than how much light reaches the eye. The composition of that light may be part of the story.
A second path remains familiar: more outdoor time. Outside, children receive the full sunlight spectrum and constantly shift focus between near and far objects. Yet the social trend toward indoor, technology-centered routines is not easy to reverse at scale. A lighting-based intervention could offer a more passive route if future studies confirm the animal data in children.
A Daycare Trial Would Test the Next Step
The next phase is expected to move from animal rooms into daycare settings. Improved lighting systems would be installed in participating centers, and children would be followed over time to compare myopia rates with those seen in centers using conventional lighting. That design would address the question that still matters most: whether indigo-enriched lighting can prevent nearsightedness in children, not just in a near-primate model.
The Cincinnati group has already taken an earlier step toward spectrum-based lighting in clinical care. In 2021, the hospital became the first pediatric center to install a programmable, full-spectrum lighting system in its neonatal intensive care unit. That effort is still being studied. Special lamps already exist for circadian applications such as jet lag, but products tailored specifically to myopia prevention are not yet widely available.
For now, the study points to a plausible and scalable prevention strategy, but it remains preclinical. The central unanswered issue is not whether indigo light can alter eye growth in tree shrews; it already did. The question is whether a redesigned indoor spectrum can do the same in children without creating new safety or implementation problems.
The authors disclosed pending patents tied to lighting devices related to the work, and one investigator is also a founder and chief scientific officer of a startup connected to the research. Those disclosures do not weaken the experiment itself, but they do frame the commercial path that may follow if pediatric trials reproduce the effect.